Stocks News

LAST PRICE
136.1500
TODAY'S CHANGE (%)
Trending Down-0.5500 (-0.4023%)

Bid / Lots
136.3500/ 1
Ask / Lots
139.0000/ 1
Open / Previous Close
138.0000 / 136.7000
Day Range
Low 135.2300
High 138.6850
52 Week Range
Low 89.0400
High 148.3699
Volume
712,827
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- DJ S&P 500 Futures Rise In Premarket Trading; GameStop, Squarespace Lead, from 12 hours ago by Dow Jones
  12 hours ago by Dow Jones
  Companies Mentioned: GME, INCY, MKSI, NBIX, BPOP, SQSP, BROS
  
  This article was automatically generated by Barrons.com using technology from Automated Insights.
  
  With U.S. stock markets set to open in two hours, GameStop Corp. Cl A (GME) was up 38.1% in pre-market trading, and Squarespace Inc. (SQSP) was up 12.6%.
May 9, 2024
- Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by PR Newswire
  9:45AM ET on Thursday May 09, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients
  -- Comprehensive Literature Review Identified Potential Psychological and Cognitive Impact of High Glucocorticoid Doses in CAH Patients
- Neurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by Dow Jones
  9:45AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter), and Facebook.
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by PR Newswire
  8:30AM ET on Thursday May 09, 2024 by PR Newswire
  Companies Mentioned: NBIX
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by Neurocrine Biosciences.
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by Dow Jones
  8:30AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
  
  PR Newswire
  
  SAN DIEGO, May 9, 2024

Today
- Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: BMRN
- Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: QGEN
May 10, 2024
- United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing, from 4:41PM ET on Friday May 10, 2024 by MT Newswires
  4:41PM ET on Friday May 10, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 8, 2024
- United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing, from 5:15PM ET on Wednesday May 08, 2024 by MT Newswires
  5:15PM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: MEDP
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 8:01AM ET on Wednesday May 08, 2024 by PR Newswire
  8:01AM ET on Wednesday May 08, 2024 by PR Newswire
  Companies Mentioned: BMRN
May 7, 2024
- United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 5:00PM ET on Tuesday May 07, 2024 by MT Newswires
  5:00PM ET on Tuesday May 07, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 6, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires
  4:47PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: BMRN
- United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR
- United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Today

DJ S&P 500 Futures Rise In Premarket Trading; GameStop, Squarespace Lead, from 12 hours ago by Dow Jones

May 9, 2024

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by PR Newswire

Neurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by Dow Jones

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by PR Newswire

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by Dow Jones

Peers Headlines

Today

Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing, from 3 hours ago by MT Newswires

Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 15 hours ago by MT Newswires

May 10, 2024

United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing, from 4:41PM ET on Friday May 10, 2024 by MT Newswires

May 8, 2024

United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing, from 5:15PM ET on Wednesday May 08, 2024 by MT Newswires

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV, from 8:01AM ET on Wednesday May 08, 2024 by PR Newswire

May 7, 2024

United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 5:00PM ET on Tuesday May 07, 2024 by MT Newswires

May 6, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires